Come dive into one of the curiously delightful conversations overheard at National Geographic’s headquarters, as we follow explorers, photographers, and scientists to the edges of our big, weird, beautiful world. Hosted by Peter Gwin and Amy Briggs.
…
continue reading
コンテンツは Dr Neil Love によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Dr Neil Love またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Player FM -ポッドキャストアプリ
Player FMアプリでオフラインにしPlayer FMう!
Player FMアプリでオフラインにしPlayer FMう!
Gastrointestinal Cancers | Oncology Today with Dr Neil Love: Key Presentations on Gastrointestinal Cancers from the 2021 ASCO Annual Meeting
Manage episode 298860934 series 2513286
コンテンツは Dr Neil Love によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Dr Neil Love またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Featuring an interview with Dr Kristen Ciombor, including the following topics:
- Final overall survival from the Phase III KN177 study evaluating pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer (mCRC) (0:00)
- Trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing mCRC: Final results from the DESTINY-CRC01 study (1:54)
- My Pathway HER2 basket study: Pertuzumab with trastuzumab for patients with HER2-positive advanced solid tumors in a large, tissue-agnostic cohort (3:49)
- Nivolumab with ipilimumab or nivolumab with chemotherapy versus chemotherapy alone as first-line treatment for advanced esophageal squamous cell carcinoma: First results from the CheckMate 648 study (6:38)
- First-line nivolumab with chemotherapy versus chemotherapy alone for advanced gastric cancer, gastroesophageal junction (GEJ) cancer or esophageal adenocarcinoma: Expanded efficacy and safety data from the CheckMate 649 study (8:15)
- Adjuvant nivolumab for resected esophageal or GEJ cancer after neoadjuvant chemoradiation therapy: Expanded efficacy and safety analyses from the CheckMate 577 study (9:57)
- Trastuzumab deruxtecan in patients with HER2-positive advanced gastric or GEJ adenocarcinoma: Final overall survival results from the Phase II DESTINY-Gastric01 study (11:10)
- Pembrolizumab with trastuzumab and chemotherapy for HER2-positive metastatic gastric or GEJ cancer: Initial findings of the Phase III KEYNOTE-811 study (12:27)
- FIGHT: A Phase II study of bemarituzumab combined with modified FOLFOX6 as first-line therapy for FGFR2b-positive advanced gastric or GEJ adenocarcinoma (15:24)
- IMbrave150 trial: Exploratory analysis of the association between treatment response and overall survival among patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab/bevacizumab compared to sorafenib (16:19)
- Updated results of a Phase Ib study of regorafenib with pembrolizumab for first-line treatment of advanced HCC (17:36)
- Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Update of the FIGHT-202 study (18:39)
- NIFTY: A Phase II study of liposomal irinotecan in combination with fluorouracil and leucovorin for patients with metastatic biliary tract cancer after disease progression on gemcitabine/cisplatin (20:14)
- Preoperative chemoradiation therapy to improve overall survival for patients with pancreatic cancer: Long-term results of the Phase III PREOPANC trial (21:40)
- Efficacy and safety of zenocutuzumab in patients with advanced pancreatic cancer and other solid tumors harboring NRG1 fusions (22:54)
1283 つのエピソード
Manage episode 298860934 series 2513286
コンテンツは Dr Neil Love によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Dr Neil Love またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Featuring an interview with Dr Kristen Ciombor, including the following topics:
- Final overall survival from the Phase III KN177 study evaluating pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer (mCRC) (0:00)
- Trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing mCRC: Final results from the DESTINY-CRC01 study (1:54)
- My Pathway HER2 basket study: Pertuzumab with trastuzumab for patients with HER2-positive advanced solid tumors in a large, tissue-agnostic cohort (3:49)
- Nivolumab with ipilimumab or nivolumab with chemotherapy versus chemotherapy alone as first-line treatment for advanced esophageal squamous cell carcinoma: First results from the CheckMate 648 study (6:38)
- First-line nivolumab with chemotherapy versus chemotherapy alone for advanced gastric cancer, gastroesophageal junction (GEJ) cancer or esophageal adenocarcinoma: Expanded efficacy and safety data from the CheckMate 649 study (8:15)
- Adjuvant nivolumab for resected esophageal or GEJ cancer after neoadjuvant chemoradiation therapy: Expanded efficacy and safety analyses from the CheckMate 577 study (9:57)
- Trastuzumab deruxtecan in patients with HER2-positive advanced gastric or GEJ adenocarcinoma: Final overall survival results from the Phase II DESTINY-Gastric01 study (11:10)
- Pembrolizumab with trastuzumab and chemotherapy for HER2-positive metastatic gastric or GEJ cancer: Initial findings of the Phase III KEYNOTE-811 study (12:27)
- FIGHT: A Phase II study of bemarituzumab combined with modified FOLFOX6 as first-line therapy for FGFR2b-positive advanced gastric or GEJ adenocarcinoma (15:24)
- IMbrave150 trial: Exploratory analysis of the association between treatment response and overall survival among patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab/bevacizumab compared to sorafenib (16:19)
- Updated results of a Phase Ib study of regorafenib with pembrolizumab for first-line treatment of advanced HCC (17:36)
- Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Update of the FIGHT-202 study (18:39)
- NIFTY: A Phase II study of liposomal irinotecan in combination with fluorouracil and leucovorin for patients with metastatic biliary tract cancer after disease progression on gemcitabine/cisplatin (20:14)
- Preoperative chemoradiation therapy to improve overall survival for patients with pancreatic cancer: Long-term results of the Phase III PREOPANC trial (21:40)
- Efficacy and safety of zenocutuzumab in patients with advanced pancreatic cancer and other solid tumors harboring NRG1 fusions (22:54)
1283 つのエピソード
すべてのエピソード
×プレーヤーFMへようこそ!
Player FMは今からすぐに楽しめるために高品質のポッドキャストをウェブでスキャンしています。 これは最高のポッドキャストアプリで、Android、iPhone、そしてWebで動作します。 全ての端末で購読を同期するためにサインアップしてください。